<?xml version="1.0" encoding="UTF-8"?>
<p>It has been demonstrated in multiple studies that HO-1 genetic polymorphisms, specifically the GT dinucleotide repeat in the promoter region, regulates the inducibility (i.e., transcription) of HO-1 to ROS [
 <xref rid="B46-antioxidants-09-00636" ref-type="bibr">46</xref>,
 <xref rid="B47-antioxidants-09-00636" ref-type="bibr">47</xref>,
 <xref rid="B48-antioxidants-09-00636" ref-type="bibr">48</xref>,
 <xref rid="B49-antioxidants-09-00636" ref-type="bibr">49</xref>,
 <xref rid="B50-antioxidants-09-00636" ref-type="bibr">50</xref>,
 <xref rid="B51-antioxidants-09-00636" ref-type="bibr">51</xref>,
 <xref rid="B52-antioxidants-09-00636" ref-type="bibr">52</xref>]. Individuals with larger GT repeats have been found to be more susceptible to diseases that involve the endothelium of the cardiovascular system including abdominal aortic aneurysms, atherosclerosis, and coronary artery disease, especially in diabetes and obesity [
 <xref rid="B46-antioxidants-09-00636" ref-type="bibr">46</xref>,
 <xref rid="B49-antioxidants-09-00636" ref-type="bibr">49</xref>,
 <xref rid="B50-antioxidants-09-00636" ref-type="bibr">50</xref>]. Other diseases such as emphysema and melanoma were also more prevalent in patients with larger GT repeat sequences [
 <xref rid="B47-antioxidants-09-00636" ref-type="bibr">47</xref>,
 <xref rid="B48-antioxidants-09-00636" ref-type="bibr">48</xref>]. Whether or not shorter GT alleles are associated with higher levels of HO-1 and better glycemic control remain controversial, but there is agreement that if any correlation is suspected, the shorter GT allele is associated with mild beneficial glycemic control [
 <xref rid="B52-antioxidants-09-00636" ref-type="bibr">52</xref>,
 <xref rid="B53-antioxidants-09-00636" ref-type="bibr">53</xref>].
</p>
